# Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

> **NCT01015222** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 122 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01015222
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2022-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01015222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01015222, "Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01015222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*